Juvenile myasthenia gravis is a rare disorder acquired in childhood, representing 10% to 15% of all cases of myasthenia gravis. Like the adult form, it is generally characterized by an autoimmune attack on acetylcholine receptors at the neuromuscular junction. Most patients present with ptosis, diplopia, and fatigability. More advanced cases may also have bulbar problems and limb weakness. Left untreated, the disease may progress to paralysis of the respiratory muscles. Early recognition of this disease helps avoid unnecessary testing, prevent undue parental anxiety, and stop the progression of symptoms. Here, we relate the clinical course and current status of 3 patients with juvenile myasthenia gravis, discuss the disease in general, and review current treatment modalities.
Osserman KE, Teng P.Studies in myasthenia gravis: neonatal and juvenile types. J Mt Sinai Hosp N Y. 1956;23:711-727.
2.
Oosterhuis HJThe natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52: 1121-1127.
3.
Robertson NP , Deans J., Compston DAMyasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry . 1998 ;65:492-496.
4.
Kalb B., Matell G., Pirskanen R., Lambe M.Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology. 2002;21:221-225.
5.
Andrews PI, Massey JM, Howard JF Jr, Sanders DBRace, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994;44:1208-1214.
6.
Drachman DBMyasthenia gravis. N Engl J Med. 1994 ;330: 1797-1810.
7.
Padua L., Tonali P., Aprile I., Caliandro P., Bartoccioni E., Evoli A.Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients. Eur J Neurology. 2006;13:273-276.
8.
Niks EH, Kuks JBM, Roep BO, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14DQ5. Neurology. 2006;66:1772-1774.
9.
Lindstrom J. , Seybold ME, Lennon VA, Whittingham S., Duane DDAntibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic values. Neurology. 1976;26:1054-1059.
10.
Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A.Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med . 2001;7:365-368.
11.
Boneva N., Frankian-Cuvelier M., Bidault J., Brenner T., BerrihAknin S.Major pathogenic effects of anti-MuSK anti-bodies in myasthenia gravis . J Neuroimmunology. 2006;177:119-131.
12.
Cogan DGMyasthenia gravis. A review of the disease and a description of lid twitch as a characteristic sign. Arch Ophthalmol. 1965;74:217-221.
13.
Mullaney P. , Vajsar J., Smith R., Buncic JRThe natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthamology. 2000;107: 504-510.
14.
Grob D., Arsura EL, Brunner NG, Namba T.The course of myasthenia gravis and therapies affecting outcome. Ann N Y Sci. 1987;505:472-499.
15.
Rodriguez M. , Gomez MR, Howard FM, Taylor F.Myasthenia gravis in children: long-term follow-up . Ann Neurol. 1981;13: 504-510.
16.
Deymeer F., Gungor-Tuncer O., Yilmaz V., et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007;68:609-611.
17.
Farrugia ME , Robson MD, Clover L., et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis . Brain. 2006;129: 1481-1492.
18.
Osserman KEMyasthenia Gravis. New York, NY: Grune & Stratton; 1958.
19.
Padua L., Tonali P., Aprile I., Caliandro P., Bartoccioni E., Evoli A.Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients. Eur J Neurology. 2006;13:273-276.
20.
Meriggioli MN, Sanders DBAdvances in the diagnosis of neuromuscular junction disorders. Amj Phys Med Rehab. 2005 ;84: 627-638.
21.
Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JMThe effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217:131-133.
Robinson J., Kothari MJMyasthenia gravis and related disorders. In: Rakel RE, Bope ET, eds. Conn's Current Therapy2008. 60th ed. Philadelphia, PA: Saunders Elsevier ; 2008. Available at: http://www.mdconsult.com.echo.louisville.edu/das/book/0/view/1621/471.html.
24.
Shrager JB, Deeb ME, Mick R., et al. Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy. Ann Thorac Surg. 2002;74:320-326.
25.
Lindner A., Schalke B., Toyka KVOutcome in juvenile-onset myasthenia gravis: a retrospective study with long-term followup of 79 patients. Neural. 1997;244:515-520.
Shrager JB, Nathan D., Brinster CJ, et al. Outcomes after 151 extended transcervical thymectomies for myasthenia gravis. Ann Thorac Surg. 2006;82:1863-1869.
28.
Clinicaltrials.gov: A service of the U.S.National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/results?term= myasthenia+gravis. Accessed June 18, 2008.
29.
Nagayasu T. , Yamayoshi T., Matsumoto K., et al. Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis. Jpn J Thorac Cardiovasc Surg. 2005;53:2-7.
30.
Sanders DB, El-Salem K., Massey JM, McConville J., Vincent A.Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978-1980.
31.
Jenson P., Bril V.A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscl Dis. 2008;9: 352-355.
32.
Selcen D., Dabrowski ER, Michon AM, Nigro MAHigh-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis . Pediatr Neurol. 2000;22:40-43.
33.
Nagaishi A. , Yukitake M., Kuroda Y.Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med. 2008;47:731-736.
